Seifi, M. | Search bioRxiv

bioRxiv2020

Syndapin-2 mediates amyloid-β transcytosis at the brain endothelium: implications in Alzheimer's disease

A deficient transport of amyloid-(A{beta}) across the blood-brain barrier (BBB), and its diminished clearance from the brain, contributes to neurodegenerative and vascular pathologies, including Alzheimers (AD) and cerebral angiopathy, respectively. At the BBB, A{beta} efflux transport is associated with the low-density receptor-related protein 1 (LRP1). However, the precise mechanisms governing A{beta} transport across the BBB, in health and disease, remain to be fully understood. Recent evidence indicates that the LRP1 transcytosis occurs through a tubulation-mediated mechanism stabilised by syndapin-2. Here, we show that syndapin-2 is associated with A{beta} clearance via LRP1 across the BBB. We further demonstrate that risk factors for AD, A{beta} expression and ageing, are associated with a decline in the native expression of syndapin-2 within brain endothelium. Our data reveal that the syndapin-2-mediated pathway, and its balance with the endosomal sorting, are important for A{beta} clearance proposing a measure to evaluate AD and ageing, as well as a target for counteracting A{beta} build-up. Moreover, we provide evidence for the impact of the avidity of A{beta} assemblies in their trafficking across the brain endothelium and in LRP1 expression levels, which may affect the overall clearance of A{beta} across the BBB.

neuroscience↗

bioRxiv2020

Identification of amyloid beta oligomers in locus coeruleus (LC) neurons of Alzheimer's patients and their impact on LC oxidative stress, inhibitory neurotransmitter receptors and neuronal excitability

Amyloid {beta} oligomers (A{beta}O) are potent modulators of two key Alzheimers pathological processes, namely synaptic dysfunction and tau tangle formation in various brain regions. Remarkably, the impact of A{beta}O in one of the earliest brain regions to exhibit Alzheimers pathology, the locus coeruleus (LC), remains to be determined. Of particular importance is the effect of A{beta}O on the excitability of individual LC neurons. This parameter determines brain-wide noradrenaline (NA) release, and thus NA-mediated brain functions, including cognition, emotion and immune function, which are all severely compromised in Alzheimers. Using a mouse model of increased A{beta} production (APP-PSEN1), together with correlative histopathological analyses in post mortem Alzheimers patient samples, we determined the impact of A{beta} pathology on various correlates of LC neuronal integrity. A{beta}O immunoreactivity in the LC of APP-PSEN1 mice was replicated in patient samples, presenting as individual clusters located both intraneuronally, in mitochondrial compartments, as well as extracellularly in association with inhibitory synapses. No specific signal was detected in either patient control or wild type mouse samples. Accompanying this A{beta}O expression profile was LC neuronal hyperexcitability and indicators of oxidative stress in APP-PSEN1 mice. LC hyperexcitability arose from a diminished inhibitory effect of GABA, due to impaired expression and function of the GABA-A receptor (GABAAR) 3 subunit. Importantly, this altered LC 3-GABAAR expression profile overlapped with A{beta}O expression in both APP-PSEN1 mice and Alzheimers patient samples. Finally, strychnine-sensitive glycine receptors (GlyRs) remained resilient to A{beta}O-induced changes and their activation reversed LC hyperexcitability. Alongside this first demonstration of A{beta}O expression in the LC of Alzheimers patients, the study is also first to reveal a direct association between A{beta}O and LC neuronal excitability. GlyR-3-GABAAR modulation of A{beta}O-dependent LC hyperexcitability could delay the onset of cognitive and psychiatric symptoms arising from LC-NA deficits, thereby significantly diminishing the disease burden for Alzheimers patients.

neuroscience↗